Expression of p53 in ground‑glass nodule of lung cancer and non‑lung cancer patients

Teng,Zhihua; Chen,Wen; Yang,Dongyong; Zhang,Zhenghua; Zhu,Lifei; Wu,Fubing

doi:10.3892/ol.2018.9797

Expression of p53 in ground‑glass nodule of lung cancer and non‑lung cancer patients

Authors:
- Zhihua Teng
- Wen Chen
- Dongyong Yang
- Zhenghua Zhang
- Lifei Zhu
- Fubing Wu
View Affiliations

Affiliations: Department of Thoracic Surgery, The Second Affiliated Hospital of Zhejiang University School of Medicine,Hangzhou, Zhejiang 310009, P.R. China, Department of TCM, The Second Affiliated Hospital of Fujian Medical University, Respiratory Medicine Center of Fujian Province, Quanzhou, Fujian 362000, P.R. China, Department of Pulmonary and Critical Care Medicine, The Second Affiliated Hospital of Fujian Medical University, Respiratory Medicine Center of Fujian Province, Quanzhou, Fujian 362000, P.R. China, Department of Oncology,Jingan District Central Hospital, Shanghai 200040, P.R. China, Center of Cancer, Shanghai General Hospital,Shanghai Jiao Tong University, Shanghai 201620, P.R. China, Department of Medical Oncology, Sir Run Run Hospital,Nanjing Medical University, Nanjing, Jiangsu 211166, P.R. China
Published online on: December 5, 2018 https://doi.org/10.3892/ol.2018.9797
Pages: 1559-1564
Copyright: © Teng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study investigated the expression of p53 in ground‑glass nodule (GGN) of lung cancer and non‑lung cancer patients, and explored the correlation with prognosis. A total of 120 GGN patients admitted to the Department of Respiratory Medicine in the Second Affiliated Hospital of Zhejiang University School of Medicine during the period from March 2010 to March 2014 were selected. These patients included 60 lung cancer patients and 60 non‑tumor patients. Biopsy or surgical specimens were collected. Fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) were used to detect p53 gene and protein expression in the two groups of GGN tissues. All patients were followed up for 3 years and the relationship between p53 protein expression and the overall survival (OS) of the two groups of patients was analyzed. In GGN cells of non‑cancer patients, p53 absence was observed in 6 cases and the absence rate was 10.0%. In GGN cells of cancer patients, the absence rate was significantly higher than that of non‑cancer GGN group (p<0.05). The positive rate of p53‑positive cases in non‑tumor patients GGN group was lower than that of in GGN tissues of lung cancer patients (p<0.05). There were no deaths in the GGN non‑cancer group (n=60) within 3 years, while 43 deaths occurred in GGN lung cancer group. The median survival time and the 3‑year survival rate of patients with p53 positive was lower than that of p53‑negative patients (p<0.05). p53 was overexpressed in GGN of lung cancer patients, and p53 overexpression is significantly correlated with poor prognosis of lung cancer patients. p53 plays an important role in transformation from GGN to lung cancer. Detection of p53 expression in GGN tissue may provide guidance for the diagnosis and prognosis of lung cancer.

View Figures

View References

1	Grunnet M and Sorensen JB: Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer. 76:138–143. 2012. View Article : Google Scholar : PubMed/NCBI
2	Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM and Sicks JD: National Lung Screening Trial Research Team: Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 365:395–409. 2011. View Article : Google Scholar : PubMed/NCBI
3	Wood DE: National Comprehensive Cancer Network (NCCN) clinical practice guidelines for lung cancer screening. Thorac Surg Clin. 25:185–197. 2015. View Article : Google Scholar : PubMed/NCBI
4	Suzuki K, Asamura H, Kusumoto M, Kondo H and Tsuchiya R: ‘Early’ peripheral lung cancer: Prognostic significance of ground glass opacity on thin-section computed tomographic scan. Ann Thorac Surg. 74:1635–1639. 2002. View Article : Google Scholar : PubMed/NCBI
5	Li F, Sone S, Abe H, Macmahon H and Doi K: Malignant versus benign nodules at CT screening for lung cancer: Comparison of thin-section CT findings. Radiology. 233:793–798. 2004. View Article : Google Scholar : PubMed/NCBI
6	Aoki T, Tomoda Y, Watanabe H, Nakata H, Kasai T, Hashimoto H, Kodate M, Osaki T and Yasumoto K: Peripheral lung adenocarcinoma: Correlation of thin-section CT findings with histologic prognostic factors and survival. Radiology. 220:803–809. 2001. View Article : Google Scholar : PubMed/NCBI
7	Hattori A, Suzuki K, Matsunaga T, Fukui M, Tsushima Y, Takamochi K and Oh S: Tumour standardized uptake value on positron emission tomography is a novel predictor of adenocarcinoma in situ for c-stage IA lung cancer patients with a part-solid nodule on thin-section computed tomography scan. Interact Cardiovasc Thorac Surg. 18:329–334. 2014. View Article : Google Scholar : PubMed/NCBI
8	Detterbeck FC, Marom EM, Arenberg DA, Franklin WA, Nicholson AG, Travis WD, Girard N, Mazzone PJ, Donington JS, Tanoue LT, et al: The IASLC Lung Cancer Staging Project: Background data and proposals for the application of TNM staging rules to lung cancer presenting as multiple nodules with ground glass or lepidic features or a pneumonic type of involvement in the forthcoming eighth edition of the TNM classification. J Thorac Oncol. 11:666–680. 2016. View Article : Google Scholar : PubMed/NCBI
9	Lee HY, Choi YL, Lee KS, Han J, Zo JI, Shim YM and Moon JW: Pure ground-glass opacity neoplastic lung nodules: Histopathology, imaging, and management. AJR Am J Roentgenol. 202:W224–33. 2014. View Article : Google Scholar : PubMed/NCBI
10	Goo JM, Park CM and Lee HJ: Ground-glass nodules on chest CT as imaging biomarkers in the management of lung adenocarcinoma. AJR Am J Roentgenol. 196:533–543. 2011. View Article : Google Scholar : PubMed/NCBI
11	Harris CC: p53 tumor suppressor gene: At the crossroads of molecular carcinogenesis, molecular epidemiology, and cancer risk assessment. Environ Health Perspect. 104 Suppl 3:435–439. 1996. View Article : Google Scholar : PubMed/NCBI
12	Kakeji Y, Korenaga D, Tsujitani S, Baba H, Anai H, Maehara Y and Sugimachi K: Gastric cancer with p53 overexpression has high potential for metastasising to lymph nodes. Br J Cancer. 67:589–593. 1993. View Article : Google Scholar : PubMed/NCBI
13	Tao Y, Lu L, Dewan M, Chen AY, Corso J, Xuan J, Salganicoff M and Krishnan A: Multi-level ground glass nodule detection and segmentation in CT lung images. Med Image Comput Comput Assist Interv. 12:715–723. 2009.PubMed/NCBI
14	Zhou Q, Fan Y, Wang Y, Qiao Y, Wang G, Huang Y, Wang X, Wu N, Zhang G, Zheng X, et al: China national guideline of classification, diagnosis and treatment for lung nodules (2016 version). Zhongguo Fei Ai Za Zhi. 19:793–798. 2016.(In Chinese). PubMed/NCBI
15	Wu C, Zhao C, Yang Y, He Y, Hou L, Li X, Gao G, Shi J, Ren S, Chu H, et al: High discrepancy of driver mutations in patients with NSCLC and synchronous multiple lung ground-glass nodules. J Thorac Oncol. 10:778–783. 2015. View Article : Google Scholar : PubMed/NCBI
16	Zhang Y, Qiang JW, Ye JD, Ye XD and Zhang J: High resolution CT in differentiating minimally invasive component in early lung adenocarcinoma. Lung Cancer. 84:236–241. 2014. View Article : Google Scholar : PubMed/NCBI
17	Muller PA and Vousden KH: Mutant p53 in cancer: New functions and therapeutic opportunities. Cancer Cell. 25:304–317. 2014. View Article : Google Scholar : PubMed/NCBI
18	Lane DP, Cheok CF and Lain S: p53-based cancer therapy. Cold Spring Harb Perspect Biol. 2:a0012222010. View Article : Google Scholar : PubMed/NCBI
19	Jolly KW, Malkin D, Douglass EC, Brown TF, Sinclair AE and Look AT: Splice-site mutation of the p53 gene in a family with hereditary breast-ovarian cancer. Oncogene. 9:97–102. 1994.PubMed/NCBI
20	Olivier M, Hollstein M and Hainaut P: TP53 mutations in human cancers: Origins, consequences, and clinical use. Cold Spring Harb Perspect Biol. 2:a0010082010. View Article : Google Scholar : PubMed/NCBI